Commonwealth Fund March 12, 2020
Jesse C. Baumgartner, Lovisa Gustafsson

Toplines

Comparative effectiveness research can be a powerful tool to bring down the cost of drugs

An increased role for comparative effectiveness research would help U.S. payers lower drug costs and prioritize the most effective medications

Most of us are aware that the United States spends far more on prescription drugs than other high-income countries do. Probably less well known is that Americans also use more drugs and treatments that provide only marginal clinical benefit. So why do people around the world not only spend less, but receive medicines that are more effective?

In part, it’s because most other countries rely on comparative effectiveness research (CER) to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: ACA (Affordable Care Act), CMS, Congress / White House, Govt Agencies, Insurance, Patient / Consumer, Payer, Provider, Public Exchange
In Their Own Words Marketplace Enrollees Would Struggle to Afford Premium Hikes If Congress
Trump administration targets ACA 'program integrity' with new rule, slashes navigator funding
CMS cuts funding to ACA Navigator program
Eliminating the ACA Medicaid Expansion Match Could Reduce Total Medicaid Spending by Up To $1.9 Trillion Over 10 Years and End Coverage for 20 Million People
GOP calls for $1.5T in cuts, much of which could come from healthcare

Share This Article